甘露寡聚糖类化合物及其作为抗RNA病毒药物的应用

    公开(公告)号:WO2018103680A1

    公开(公告)日:2018-06-14

    申请号:PCT/CN2017/114906

    申请日:2017-12-07

    发明人: 陈敏

    摘要: 一类甘露寡聚糖化合物及其作为抗RNA病毒药物的应用,式I化合物对丙型肝炎病毒(HCV)和呼吸道合胞病毒(RSV)均显示出极强的抑制活性。式I化合物具有如式(I)所示结构。其中n选自0至5的整数;U选自C、N、O或S;每个R、R 1 、R 2 各自独立地选自烷基、烯基、炔基、酰基、芳基、硅基、甲磺酰基(Ms)、对甲苯磺酰基(Ts)、SO 3 M、PO 3 M 2 或H,M为H、Na或K,或者空间上接近的两个RO基团或者RO与R 1 O基团共同形成(II)或(III),R 3 为任选被甲基、甲氧基、羟基、氨基、卤素或苯基取代的苯基,或者UR 2 基团一起是氟、氯、溴、碘或N 3 。

    OLIGOSACCHARIDE COMPOSITION FOR BINDING TO LECTINS
    3.
    发明申请
    OLIGOSACCHARIDE COMPOSITION FOR BINDING TO LECTINS 审中-公开
    用于结合凝集素的低聚糖组合物

    公开(公告)号:WO2017109023A1

    公开(公告)日:2017-06-29

    申请号:PCT/EP2016/082289

    申请日:2016-12-22

    摘要: The present invention relates to a method of preparing an oligosaccharide composition, said method comprising the steps of: (a)providing a pectin; and (b)performing, in any order, conversion of carboxylic acid groups to the corresponding alcohols and cleavage of glycosidic bonds under conditions suitable to give an oligosaccharide composition. The present invention also relates to an oligosaccharide composition obtainable or being obtained by using such a method of preparing an oligosaccharide composition. The present invention further relates to a method of preparing a coupling product of an oligosaccharide composition. The present invention is also directed to a coupling product of an oligosaccharide composition. The present invention also relates to pharmaceutical compositions comprising the oligosaccharide composition or the coupling product of an oligosaccharide composition as well as medical uses and diagnostic uses.

    摘要翻译: 本发明涉及制备寡糖组合物的方法,所述方法包括以下步骤:(a)提供果胶; 和(b)以任何顺序进行羧酸基团向相应醇的转化和在适于产生寡糖组合物的条件下糖苷键的切割。 本发明还涉及可通过使用这种制备寡糖组合物的方法获得或获得的寡糖组合物。 本发明进一步涉及制备寡糖组合物的偶联产物的方法。 本发明还涉及寡糖组合物的偶联产物。 本发明还涉及包含寡糖组合物或寡糖组合物的偶联产物以及医学用途和诊断用途的药物组合物。

    VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5
    5.
    发明申请
    VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 审中-公开
    抗菌肽类抗生素5

    公开(公告)号:WO2016198170A1

    公开(公告)日:2016-12-15

    申请号:PCT/EP2016/051608

    申请日:2016-01-26

    摘要: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae , and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

    摘要翻译: 本发明涉及与肺炎链球菌血清型5荚膜多糖及其结合物的重复单元相关的通式(I)的明确定义的合成糖。 含有所述缀合物的缀合物和药物组合物可用于预防和/或治疗与肺炎链球菌相关的疾病,更具体地针对与肺炎链球菌血清型5相关的疾病。此外,通式(I)的合成糖可用作标记 用于检测针对肺炎链球菌的抗体的免疫测定。

    IMPROVED COMPOSITIONS AND METHODS FOR BOROCARBOHYDRATE COMPLEXES
    7.
    发明申请
    IMPROVED COMPOSITIONS AND METHODS FOR BOROCARBOHYDRATE COMPLEXES 审中-公开
    改进的组合物和方法用于硼氢化合物复合物

    公开(公告)号:WO2016032543A1

    公开(公告)日:2016-03-03

    申请号:PCT/US2014/055702

    申请日:2014-09-15

    发明人: HUNTER, John M.

    IPC分类号: C07F5/02 C07H1/00 A61K31/70

    摘要: Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt% di-complex and a boric acid content of less than 15 wt%, and more typically less than 5 wt%. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components.

    摘要翻译: 提供了含有硼复合物的组合物,其具有改进的二配位体与硼酸的比例。 在一些实施方案中,组合物的特征在于液体形式的二 - 络合物与硼酸的比例为至少5:1,更典型地至少为10:1,干燥形式为至少20:1。 在其它实施方案中,组合物的特征在于最小含量为80重量%的二配合物和硼酸含量小于15重量%,更通常小于5重量%。 认为考虑的组合物具有改善的生物活性并减少不需要的组分的含量。